{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEPLISAV-B%C2%AE&page=2",
    "query": {
      "intervention": "HEPLISAV-B®",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 43,
    "total_pages": 5,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEPLISAV-B%C2%AE&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEPLISAV-B%C2%AE&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-30T04:49:24.550Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00474526",
      "title": "A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Meningitis, Meningococcal"
      ],
      "interventions": [
        {
          "name": "Meningococcal ACWY Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP-IPV-HBV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Hib",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Rotavirus",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pneumococcal 7-valent Conjugate Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "HAV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "MMR-V",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DTaP",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Novartis Vaccines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "2 Months",
        "sex": "ALL",
        "summary": "2 Months to 2 Months"
      },
      "enrollment_count": 4545,
      "start_date": "2007-03",
      "completion_date": "2009-11",
      "has_results": true,
      "last_update_posted_date": "2014-03-24",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 53,
      "location_summary": "Bessemer, Alabama • Birmingham, Alabama • Downey, California + 43 more",
      "locations": [
        {
          "city": "Bessemer",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Downey",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00474526"
    },
    {
      "nct_id": "NCT03934736",
      "title": "HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "End Stage Renal Disease on Hemodialysis (Diagnosis)"
      ],
      "interventions": [
        {
          "name": "HEPLISAV-B®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2019-04-22",
      "completion_date": "2021-09-15",
      "has_results": true,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 20,
      "location_summary": "Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more",
      "locations": [
        {
          "city": "Bloomfield",
          "state": "Connecticut"
        },
        {
          "city": "Middlebury",
          "state": "Connecticut"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03934736"
    },
    {
      "nct_id": "NCT00722332",
      "title": "Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hepatitis B",
        "Liver Transplantation"
      ],
      "interventions": [
        {
          "name": "HepaGam B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cangene Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 9,
      "start_date": "2008-02",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2013-11-01",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00722332"
    },
    {
      "nct_id": "NCT00734162",
      "title": "Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis B Virus (HBV)"
      ],
      "interventions": [
        {
          "name": "Tenofovir disoproxil fumarate (TDF)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "12 Years to 17 Years"
      },
      "enrollment_count": 106,
      "start_date": "2008-12",
      "completion_date": "2015-12",
      "has_results": true,
      "last_update_posted_date": "2016-09-01",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 3,
      "location_summary": "Oakland, California • Indianapolis, Indiana • Seattle, Washington",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00734162"
    },
    {
      "nct_id": "NCT01282762",
      "title": "Long-Term Study on Safety and Immunogenicity of HEPLISAV™ and Engerix-B® in Adults With Chronic Kidney Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "HEPLISAV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 147,
      "start_date": "2010-12",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 1,
      "location_summary": "Norfolk, Virginia",
      "locations": [
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01282762"
    },
    {
      "nct_id": "NCT01940471",
      "title": "Study to Compare Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF) in Participants With Chronic Hepatitis B Infection Who Are Positive for Hepatitis B e Antigen",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "HBeAg-positive Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TAF",
          "type": "DRUG"
        },
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "TDF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 875,
      "start_date": "2013-09-11",
      "completion_date": "2022-10-13",
      "has_results": true,
      "last_update_posted_date": "2023-10-10",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 10 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Jose",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01940471"
    },
    {
      "nct_id": "NCT02117934",
      "title": "Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "HEPLISAV",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Engerix-B",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dynavax Technologies Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 8374,
      "start_date": "2014-04",
      "completion_date": "2015-10",
      "has_results": true,
      "last_update_posted_date": "2019-03-20",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 40,
      "location_summary": "Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 31 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02117934"
    },
    {
      "nct_id": "NCT02979613",
      "title": "Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TAF",
          "type": "DRUG"
        },
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "TAF Placebo",
          "type": "DRUG"
        },
        {
          "name": "TDF Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 490,
      "start_date": "2016-12-29",
      "completion_date": "2020-01-30",
      "has_results": true,
      "last_update_posted_date": "2020-09-14",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 17,
      "location_summary": "Los Angeles, California • Palo Alto, California • Pasadena, California + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02979613"
    },
    {
      "nct_id": "NCT02579382",
      "title": "Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "TDF",
          "type": "DRUG"
        },
        {
          "name": "Vesatolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 192,
      "start_date": "2015-11-10",
      "completion_date": "2019-05-03",
      "has_results": true,
      "last_update_posted_date": "2020-05-18",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02579382"
    },
    {
      "nct_id": "NCT03491553",
      "title": "Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis B"
      ],
      "interventions": [
        {
          "name": "Selgantolimod",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Hepatitis B virus (HBV) OAV Therapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 48,
      "start_date": "2018-04-06",
      "completion_date": "2020-08-10",
      "has_results": true,
      "last_update_posted_date": "2021-08-19",
      "last_synced_at": "2026-09-30T04:49:24.550Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03491553"
    }
  ]
}